In this multi-center study of 987 adults with lymphoma undergoing HCT with post-transplant cyclophosphamide, outcomes were comparable between haploidentical (n=180) and matched sibling donors (MSD; n=807). Three-year rates of overall survival in haploidentical vs. MSD patients were 61% and 62%, respectively (p=0.82); progression-free survival rates were 48% and 48%, respectively (p=0.96). Cumulative incidence of chronic graft-versus-host disease (GVHD) at 1 year was significantly lower after haploidentical HCT (12% vs. 45%; p<0.001). Three-year rates of non-relapse mortality and relapse/progression were also similar, based on data from CIBMTR (Center for International Blood and Marrow Transplant Research). The authors suggest that this strategy can broaden the use of allogeneic HCT without compromising efficacy and limit the racial barriers for receiving a potentially curative treatment.
Haploidentical and Matched Related Donor HCT Result in Comparable Outcomes